IP Verse

Proteolytically Cleavable Fusion Protein Comprising A Blood Coagulation Factor - EP2256135

The patent EP2256135 was granted to CSL Behring on Mar 13, 2019. The application was originally filed on Jun 14, 2007 under application number EP10168453A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2256135

CSL BEHRING
Application Number
EP10168453A
Filing Date
Jun 14, 2007
Status
Granted And Under Opposition
Feb 8, 2019
Grant Date
Mar 13, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BIOVERATIV THERAPEUTICSDec 13, 2019ZWICKERWITHDRAWN

Patent Citations (18) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS4784950
DESCRIPTIONWO0179271
DESCRIPTIONWO0204598
DESCRIPTIONWO03059935
DESCRIPTIONWO03068934
DESCRIPTIONWO2004081053
DESCRIPTIONWO2004101740
DESCRIPTIONWO2005001025
DESCRIPTIONWO2005024044
DESCRIPTIONWO9109125
EXAMINATIONEP1816201
OPPOSITIONEP1444986
OPPOSITIONWO2004101740
SEARCHEP1444986
SEARCHWO2004021861
SEARCHWO2004101739
SEARCHWO2004101740
SEARCHWO9601653

Non-Patent Literature (NPL) Citations (13) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ALEDORT L.M., J THROMB HAEMOST, (2004), vol. 2, no. 10, pages 1700 - 1708-
DESCRIPTION- BEATTIE; DUGAICZYK, GENE, (1982), vol. 20, pages 415 - 422-
DESCRIPTION- COOKE; DAVID, J. CLIN. INVEST., (1985), vol. 76, pages 2420 - 2424-
DESCRIPTION- EWENSTEIN BM ET AL., "Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B", TRANSFUSION, (2002), vol. 42, pages 190 - 197-
DESCRIPTION- LICHENSTEIN ET AL., J. BIOL. CHEM., (1994), vol. 269, pages 18149 - 18154-
DESCRIPTION- MOLLERUP ET AL., BIOTECHNOL. BIOENG., (1995), vol. 48, pages 501 - 505-
DESCRIPTION- SHEFFIELD W.P. ET AL., BR. J. HAEMATOL, (2004), vol. 126, pages 565 - 573-
DESCRIPTION- WASLEY LC ET AL., "PACE/Furin can process the vitamin K-dependent pro-factor IX precursor within the secretory pathway", J. BIOL. CHEM., (1993), vol. 268, pages 8458 - 8465-
DESCRIPTION- WHITE GC ET AL., "Recombinant factor IX", THROMB HAEMOST., (1997), vol. 78, pages 261 - 265, XP009166039-
OPPOSITION- MCCUE et al., "Manufacturing process used to produce long-acting recombinant factor viii Fc fusion protein", Biologicals, (20150000), vol. 43, pages 213 - 219, XP055662575
OPPOSITION- PETERS et al., "Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein", Journal of Thrombosis and Haemostasis, (20120000), vol. 11, no. 1, pages 132 - 141, XP055092640
OPPOSITION- TOBY et al., "Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice", PLoS ONE, (20160000), vol. 11, no. 2, page e0148255, XP055420974
SEARCH- SHEFFIELD W P ET AL, "Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits", BRITISH JOURNAL OF HAEMATOLOGY, OXFORD, GB, (200408), vol. 126, no. 4, ISSN 0007-1048, pages 565 - 573, XP002395198 [Y] 1-33 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents